Other languages GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Real-time Estimate Cboe BZX Other stock markets 09:37:12 2024-07-03 am EDT			5-day change	1st Jan Change
2.825 ^USD	-1.91%		-2.37%	-62.35%

Jun. 27	GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650	MT
Jun. 27	GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650	Jun. 27
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia	Jun. 27
Top Midday Decliners	May. 21
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants	May. 21
Top Premarket Gainers	May. 20
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Caterpillar deja París, el cacao está menos caliente	Apr. 30
Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud	Apr. 30
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	Feb. 01
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	Dec. 04
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	Nov. 06
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
GT Biopharma, Inc. Announces Board Changes	23-05-04
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
GT Biopharma to Sell 6.5 Million Shares and Warrants, Expects Gross Proceeds of $6.5 Million	22-12-30
Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer	22-12-14
GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee	22-12-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Other languages

Filters